Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Cariprazine, potential new AAP

Posted by b2chica on May 24, 2012, at 13:19:34

Potential new AAP
after results, debating if this is just another abilify or if it allows sign advantage.

http://www.medscape.com/viewarticle/764391?sssdmh=dm1.787602&src=nldne


Oral cariprazine, which is also known as RGH-188, is a "D3-preferring dopamine D3/D2 receptor partial agonist,"
"Higher affinity for and greater receptor antagonism at D3 versus D2 receptors may be associated with antipsychotic efficacy...and beneficial effects on mood," they add.

The experimental drug also has a "low potency at other receptor sites such as 5-HT2c, histamine H1, muscarinic, and adrenergic receptor sites, which have been associated with adverse events."

As reported earlier this year by Medscape Medical News, results from 2 phase III trials showed that cariprazine was more effective than placebo in treating acute exacerbation of schizophrenia.

In a statement released at the time, the manufacturers reported that the drug is also being investigated as an adjunctive treatment for patients with major depressive disorder.


Results showed that the cariprazine group had significantly better improvement scores on the YMRS than did the placebo group (mean deviation, -4.3; P < .001) and greater improvements on the CGI-S (P < .01).

Premature discontinuance rates were 32% for those receiving cariprazine and 31% for those receiving placebo. The rates of discontinuance due to AEs were 10% and 7%, respectively.

Treatment-related AEs were reported by 80% of the cariprazine group vs 63% of the placebo group. The most common AEs for the cariprazine group (defined as &#8805;10%, which occurred at twice the rate seen in the patients receiving placebo) were akathisia, extrapyramidal disorder, tremor, dyspepsia, and vomiting.

Extrapyramidal symptom-related AEs were reported by 46% of the patients receiving cariprazine and by 12% of those receiving placebo.

"Cariprazine seems like a new and possibly improved aripiprazole," Nassir Ghaemi, MD, MPH, professor of psychiatry at Tufts University School of Medicine and director of the Mood Disorders Program at Tufts Medical Center in Boston, Massachusetts, wrote in a Medscape Connect blog post during the APA meeting.

"Will this biological twist make a clinical difference? We'll see. For now, this drug was proven effective in double-blind placebo-controlled randomized trials in acute mania and schizophrenia," said Dr. Ghaemi, who was not involved with this study.


"What is madness, but nobility of soul at odds with circumstance.
The day is on Fire, and i know the purity of pure despair."
Theodore Roethke


Share
Tweet  

Thread

 

Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:b2chica thread:1018614
URL: http://www.dr-bob.org/babble/20120522/msgs/1018614.html